Episode 43: Carolyn Magill

In this week’s episode, Carolyn Magill, CEO and board member for real-world analytics and evidence firm Aetion, speaks with MM&M’s executive editor, Marc Iskowitz. She offers her perspective on how real world evidence (RWE) is finding its footing with pharma, including an update on its RCT Duplicate collaboration with the FDA, where she sees synthetic trials ultimately carving out a niche, and how to ensure that patient privacy needs are met.